Curevo

Curevo

Private
Bothell, WashingtonHealthcare & Life Scienceshttps://www.curevovaccine.com

Last Round

Series B

Mar 17, 2025

Total Funding Raised

$196M

Momentum Score

25 /100

Company Overview

Curevo Vaccine is a biotechnology company focused on developing vaccines to mitigate the impact of infectious diseases and fulfill global medical needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

shingles vaccinesubunit vaccinenon-mRNA vaccineShingrix competitorvaccine developmentherpes zoster vaccinevaccine tolerabilityadjuvanted vaccineclinical-stage biotechchickenpox vaccinevaricella vaccinenext-generation vaccinegE protein antigenRSV vaccineinfectious disease vaccine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Curevo Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Curevo Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BMar 17, 2025
Series A ExtensionNov 16, 2022
Series AFeb 10, 2022

Key People

Founding team and executive leadership

George Simeon

CEO

Executive Team

Curevo Investors

Notable investors and investment history

InvestorRounds
Janus Henderson GroupSeries A, Series B, Series A Extension
RA Capital ManagementSeries B, Series A, Series A Extension
OrbiMedSeries B
HBM Healthcare InvestmentsSeries B
Sanofi VenturesSeries B
Adjuvant CapitalSeries A, Series B, Series A Extension
MedicxiSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2025

    Moncef Slaoui, former Operation Warp Speed advisor, named Board Chair.

  • Mar 17, 2025

    $110M round raised

Curevo Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Curevo Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Curevo's valuation, stock price, and market status.

Firmographic Details

HeadquartersBothell, Washington
Employee Range45
Year Founded2017
Last FundingMar 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.